"Transl Breast Cancer Res"[Journal] - Search Results

Year	Number of Results
2022	42
2023	38
2024	37
2025	20

1

De-escalation of axillary interventions in the management of breast cancer patients following neoadjuvant systemic treatment.

Tondare A, Thorat MA. Tondare A, et al. Transl Breast Cancer Res. 2025 Apr 27;6:14. doi: 10.21037/tbcr-24-59. eCollection 2025. Transl Breast Cancer Res. 2025. PMID: 40421155 Free PMC article. Review.

2

Breast cancer screening for transgender individuals with breast cancer susceptibility genes.

Abushalha K, Ng A, Pulipati S, Bhardwaj PV. Abushalha K, et al. Transl Breast Cancer Res. 2025 Apr 27;6:16. doi: 10.21037/tbcr-24-68. eCollection 2025. Transl Breast Cancer Res. 2025. PMID: 40421153 Free PMC article. Review.

3

Non-commonly prescribed physical exercises, disciplines and sports in breast cancer survivors: a narrative review.

Di Blasio A, Morano T, Di Marco A, Lancia F, Ditali L, Sirtori G, Pesce M, Cugusi L, Bullo V, Marini S, Grossi S, Napolitano G. Di Blasio A, et al. Transl Breast Cancer Res. 2025 Apr 27;6:19. doi: 10.21037/tbcr-24-63. eCollection 2025. Transl Breast Cancer Res. 2025. PMID: 40421152 Free PMC article. Review.

4

The role of a national cancer registry in effective implementation and monitoring of the Global Breast Cancer Initiative (GBCI) framework in Ghana: a narrative review.

Nair S, Ngwa W, Addai BW, Addai AO, Oti BA. Nair S, et al. Transl Breast Cancer Res. 2025 Apr 27;6:20. doi: 10.21037/tbcr-24-60. eCollection 2025. Transl Breast Cancer Res. 2025. PMID: 40421150 Free PMC article. Review.

5

Preoperative partial breast radiation for favorable early-stage breast cancer: a narrative review.

McDuff SGR, Stephens SJ, Champ CE, Blitzblau RC. McDuff SGR, et al. Transl Breast Cancer Res. 2025 Apr 27;6:17. doi: 10.21037/tbcr-24-43. eCollection 2025. Transl Breast Cancer Res. 2025. PMID: 40421149 Free PMC article. Review.

6

Enhancing patient education in breast surgery: artificial intelligence-powered guidance for mastopexy, augmentation, reduction, and reconstruction.

Marcaccini G, Susini P, Xie Y, Cuomo R, Pozzi M, Grimaldi L, Rozen WM, Seth I. Marcaccini G, et al. Transl Breast Cancer Res. 2025 Apr 25;6:12. doi: 10.21037/tbcr-24-67. eCollection 2025. Transl Breast Cancer Res. 2025. PMID: 40421151 Free PMC article.

7

Radiotherapy in breast cancer patients achieving nodal pathologic complete response after neoadjuvant therapy: a scoping review.

Cavalcante FP, Cardoso A, Antonini M, Zerwes FP, Millen EC, Mattar A, Brenelli FP, Frasson AL. Cavalcante FP, et al. Transl Breast Cancer Res. 2025 Apr 22;6:18. doi: 10.21037/tbcr-24-54. eCollection 2025. Transl Breast Cancer Res. 2025. PMID: 40421156 Free PMC article. Review.

8

Omission of breast surgery in exceptional responders after neoadjuvant chemotherapy-what are future possibilities?-a narrative review.

Phang F, Weiss A. Phang F, et al. Transl Breast Cancer Res. 2025 Apr 18;6:13. doi: 10.21037/tbcr-24-65. eCollection 2025. Transl Breast Cancer Res. 2025. PMID: 40421157 Free PMC article. Review.

9

Contrast-enhanced mammography in high-dense breasts: a narrative review.

Tari DU, Santarsiere M, De Lucia DR, Santonastaso R. Tari DU, et al. Transl Breast Cancer Res. 2025 Mar 10;6:15. doi: 10.21037/tbcr-24-64. eCollection 2025. Transl Breast Cancer Res. 2025. PMID: 40421154 Free PMC article. Review.

10

Breast cancer shares many epidemiological, lifestyle, and local hormonal and metabolic underpinnings with endometrial and ovarian cancer: a narrative review.

Rodríguez YM, Koomson AA, Perry RJ. Rodríguez YM, et al. Transl Breast Cancer Res. 2025 Jan 21;6:8. doi: 10.21037/tbcr-24-39. eCollection 2025. Transl Breast Cancer Res. 2025. PMID: 39980815 Free PMC article. Review.

11

Modern approaches to lymphatic surgery: a narrative review.

Zurbuchen EA, Yu N, Salibian AA. Zurbuchen EA, et al. Transl Breast Cancer Res. 2025 Jan 21;6:6. doi: 10.21037/tbcr-24-49. eCollection 2025. Transl Breast Cancer Res. 2025. PMID: 39980814 Free PMC article. Review.

12

Unveiling breast cancer disparities: comparative insights from Asian and Western populations.

Wang K, Wang S. Wang K, et al. Transl Breast Cancer Res. 2025 Jan 21;6:1. doi: 10.21037/tbcr-24-69. eCollection 2025. Transl Breast Cancer Res. 2025. PMID: 39980813 Free PMC article. No abstract available.

13

De-escalation of axillary treatment in early breast cancer-a narrative review of current trials.

Fancellu A, Giuliani G, Mulas S, Contini AM, Ariu ML, Sanna V. Fancellu A, et al. Transl Breast Cancer Res. 2025 Jan 21;6:5. doi: 10.21037/tbcr-24-45. eCollection 2025. Transl Breast Cancer Res. 2025. PMID: 39980812 Free PMC article. Review.

14

Neurological symptom management in breast cancer meningeal carcinomatosis.

Takahashi H. Takahashi H. Transl Breast Cancer Res. 2025 Jan 21;6:7. doi: 10.21037/tbcr-24-47. eCollection 2025. Transl Breast Cancer Res. 2025. PMID: 39980811 Free PMC article. Review.

15

DESTINY-Breast06 continues to explore HR⁺, HER2-negative metastatic breast cancer beyond DESTINY-Breast04.

Wang F, Yuan P. Wang F, et al. Transl Breast Cancer Res. 2025 Jan 21;6:11. doi: 10.21037/tbcr-24-51. eCollection 2025. Transl Breast Cancer Res. 2025. PMID: 39980810 Free PMC article. No abstract available.

16

Understanding the NATALEE trial-from a methodologist stand of point.

He Y. He Y. Transl Breast Cancer Res. 2025 Jan 21;6:10. doi: 10.21037/tbcr-24-32. eCollection 2025. Transl Breast Cancer Res. 2025. PMID: 39980809 Free PMC article. No abstract available.

17

Underlying factors that affect ultrasound conspicuity of breast biopsy markers: an exploratory study.

Cario J, Lee CU, Oelze ML. Cario J, et al. Transl Breast Cancer Res. 2025 Jan 21;6:2. doi: 10.21037/tbcr-24-48. eCollection 2025. Transl Breast Cancer Res. 2025. PMID: 39980808 Free PMC article.

18

Advances in antibody-drug conjugates in the treatment of advanced triple-negative breast cancer: a narrative review.

Jiang K, Wang S. Jiang K, et al. Transl Breast Cancer Res. 2025 Jan 21;6:9. doi: 10.21037/tbcr-24-38. eCollection 2025. Transl Breast Cancer Res. 2025. PMID: 39980806 Free PMC article. Review.

19

Recent advances and updated highlights in breast cancer pathologic diagnosis: a narrative review.

Liu Y. Liu Y. Transl Breast Cancer Res. 2025 Jan 21;6:3. doi: 10.21037/tbcr-24-27. eCollection 2025. Transl Breast Cancer Res. 2025. PMID: 39980805 Free PMC article. Review.

20

Targeting low-risk triple-negative breast cancer: a review on de-escalation strategies for a new era.

Carvalho FM. Carvalho FM. Transl Breast Cancer Res. 2024 Nov 27;6:4. doi: 10.21037/tbcr-24-28. eCollection 2025. Transl Breast Cancer Res. 2024. PMID: 39980807 Free PMC article. Review.

21

Precision medicine for breast cancer: advances and challenges.

Liu XY, Yu TJ, Shao ZM. Liu XY, et al. Transl Breast Cancer Res. 2024 Oct 31;5:35. doi: 10.21037/tbcr-24-35. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39534585 Free PMC article. No abstract available.

22

Strategies for the treatment of hormone receptor-positive HER2-low breast cancer based on clinical practice: a round table discussion.

Huang X, Hua Y, Sun C, Yin Y. Huang X, et al. Transl Breast Cancer Res. 2024 Oct 31;5:30. doi: 10.21037/tbcr-24-40. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39534582 Free PMC article. Review.

23

Passage dependence of NADH redox status and reactive oxygen species level in vitro in triple-negative breast cancer cell lines with different invasiveness.

Podsednik A, Xu HN, Li LZ. Podsednik A, et al. Transl Breast Cancer Res. 2024 Oct 31;5:27. doi: 10.21037/tbcr-24-36. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39534579 Free PMC article.

24

Regulation of PI3K signaling in cancer metabolism and PI3K-targeting therapy.

Han B, Lin X, Hu H. Han B, et al. Transl Breast Cancer Res. 2024 Oct 29;5:33. doi: 10.21037/tbcr-24-29. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39534586 Free PMC article. Review.

25

Breast ultrasound knobology and the knobology of twinkling for marker detection.

Lee CU, Hesley GK, Pierson TA, Higgins RL, Urban MW. Lee CU, et al. Transl Breast Cancer Res. 2024 Oct 29;5:28. doi: 10.21037/tbcr-24-30. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39534581 Free PMC article. Review.

26

Adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: one fits all?

Gianni C, Nicolò E, Cristofanilli M. Gianni C, et al. Transl Breast Cancer Res. 2024 Oct 25;5:34. doi: 10.21037/tbcr-24-41. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39534583 Free PMC article. No abstract available.

27

Pathological precision diagnosis and recent advances in HER2 low and ultralow in breast cancer: a narrative review.

Shang J, Liu Y. Shang J, et al. Transl Breast Cancer Res. 2024 Oct 21;5:29. doi: 10.21037/tbcr-24-33. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39534587 Free PMC article. Review.

28

Understanding the relationship between breast cancer, immune checkpoint inhibitors, and gut microbiota: a narrative review.

Hrubesz G, Leigh J, Ng TL. Hrubesz G, et al. Transl Breast Cancer Res. 2024 Oct 21;5:31. doi: 10.21037/tbcr-24-14. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39534584 Free PMC article. Review.

29

Narrative review on efficacy and safety of anti-angiogenesis in combination with immunotherapy in the treatment of breast cancer.

Deng X, Liu J. Deng X, et al. Transl Breast Cancer Res. 2024 Oct 12;5:32. doi: 10.21037/tbcr-24-21. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39534580 Free PMC article. Review.

30

A case report of interstitial lung disease caused by HER2-positive breast cancer patient receiving two antibody-drug conjugate drugs successively.

Xie W, Wang T, Wang X. Xie W, et al. Transl Breast Cancer Res. 2024 Oct 11;5:36. doi: 10.21037/tbcr-24-19. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39534578 Free PMC article.

31

St. Gallen International Breast Cancer Conferences & Consensus.

Thürlimann B. Thürlimann B. Transl Breast Cancer Res. 2024 Jul 25;5:22. doi: 10.21037/tbcr-24-24. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39184931 Free PMC article. No abstract available.

32

Breast cancer in pregnancy: a comprehensive review of diagnosis, management, and outcomes.

Mumtaz A, Otey N, Afridi B, Khout H. Mumtaz A, et al. Transl Breast Cancer Res. 2024 Jul 25;5:21. doi: 10.21037/tbcr-24-26. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39184929 Free PMC article. Review. No abstract available.

33

Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024.

Li J, Hao C, Wang K, Zhang J, Chen J, Liu Y, Nie J, Yan M, Liu Q, Geng C, Wang X, Wang H, Wang S, Wu J, Yin Y, Song E, Jiang Z. Li J, et al. Transl Breast Cancer Res. 2024 Jul 25;5:18. doi: 10.21037/tbcr-24-31. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39184927 Free PMC article. Review.

34

A narrative review: research progress of adjuvant intensive endocrine therapy for early breast cancer.

Ye H, Lin G, Wang X. Ye H, et al. Transl Breast Cancer Res. 2024 Jul 25;5:20. doi: 10.21037/tbcr-24-16. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39184926 Free PMC article. Review.

35

Matched-pair long-term survival analysis of male and female patients with breast cancer: a population-based study.

Mo M, Feng X, Wu C, Gong Y, Shen J, He Y, Zhou C, Wang Z, Fu C, Zheng Y. Mo M, et al. Transl Breast Cancer Res. 2024 Jul 25;5:19. doi: 10.21037/tbcr-24-3. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39184924 Free PMC article.

36

Activin A from primary breast tumors generates a pre-metastatic niche by inducing pulmonary fibrosis.

Shirakihara T, Orimo A. Shirakihara T, et al. Transl Breast Cancer Res. 2024 Jul 22;5:24. doi: 10.21037/tbcr-24-5. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39184930 Free PMC article. No abstract available.

37

Chemotherapy-induced neutropenia management in a patient with metastatic breast cancer and Shwachman-Diamond syndrome (SDS): a case report.

Morecroft R, Logothetics CN, Tarnawsky SP, Davis AA. Morecroft R, et al. Transl Breast Cancer Res. 2024 Jul 22;5:26. doi: 10.21037/tbcr-24-13. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39184925 Free PMC article.

38

Toripalimab: a new torchlight illuminating the path for metastatic triple negative breast cancer?

Park S, Ahn SG. Park S, et al. Transl Breast Cancer Res. 2024 Jul 22;5:23. doi: 10.21037/tbcr-24-4. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39184923 Free PMC article. No abstract available.

39

The optimal amino acid pattern for humans and its implications for nutrition of cancer patients.

Klement RJ. Klement RJ. Transl Breast Cancer Res. 2024 Jul 15;5:25. doi: 10.21037/tbcr-24-25. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39184928 Free PMC article. No abstract available.

40

Expert consensus on the clinical application of immunotherapy in breast cancer: 2024.

Wang K, Yang J, Wang B, Liu Q, Wang X, Yin Y, Wang H, Wang S, Hao C, Hao X, Liu Y, Jiang Z; Chinese Society of Clinical Oncology Breast Cancer Committee*; Chinese Society of Clinical Oncology Breast Cancer Committee. Wang K, et al. Transl Breast Cancer Res. 2024 Apr 29;5:9. doi: 10.21037/tbcr-24-15. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 38751677 Free PMC article. Review.

41

Breast fat grafting and cancer: a systematic review of the science behind enhancements and concerns.

Valente DS, Ely PB, Kieling L, Konzen AT, Steffen LP, Lazzaretti GS, Zanella RK. Valente DS, et al. Transl Breast Cancer Res. 2024 Apr 29;5:14. doi: 10.21037/tbcr-23-54. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 38751673 Free PMC article. Review.

42

Internal mammary lymphadenopathy in breast cancer: a narrative review and update.

Eckert KM, Boughey JC, Piltin MA. Eckert KM, et al. Transl Breast Cancer Res. 2024 Apr 29;5:11. doi: 10.21037/tbcr-24-2. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 38751672 Free PMC article. Review.

43

Circulating tumor cells et al.: towards a comprehensive liquid biopsy approach in breast cancer.

Nicolò E, Gianni C, Pontolillo L, Serafini MS, Munoz-Arcos LS, Andreopoulou E, Curigliano G, Reduzzi C, Cristofanilli M. Nicolò E, et al. Transl Breast Cancer Res. 2024 Apr 26;5:10. doi: 10.21037/tbcr-23-55. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 38751670 Free PMC article. Review.

44

Metabolomics combined with mathematical analysis reveals metabolic pathways specific to metastatic cancers.

Sato S, Yamashita T. Sato S, et al. Transl Breast Cancer Res. 2024 Apr 25;5:15. doi: 10.21037/tbcr-23-51. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 38751674 Free PMC article. No abstract available.

45

New role for GCH1 in cancer.

Cronin SJF. Cronin SJF. Transl Breast Cancer Res. 2024 Apr 24;5:16. doi: 10.21037/tbcr-23-53. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 38751681 Free PMC article. No abstract available.

46

Evolution of localization methods for non-palpable breast lesions: a literature review from a translational medicine perspective.

Cheung BHH, Co M, Lui TTN, Kwong A. Cheung BHH, et al. Transl Breast Cancer Res. 2024 Apr 15;5:12. doi: 10.21037/tbcr-23-49. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 38751684 Free PMC article. Review.

47

The need for a holistic guide to prevent and manage radiation dermatitis in patients' with breast cancer: a case report.

Sherman DW. Sherman DW. Transl Breast Cancer Res. 2024 Mar 8;5:17. doi: 10.21037/tbcr-23-52. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 38751678 Free PMC article.

48

Breast surgery after neoadjuvant systemic therapy.

Pawloski KR, Barrio AV. Pawloski KR, et al. Transl Breast Cancer Res. 2024 Mar 4;5:13. doi: 10.21037/tbcr-23-50. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 38751679 Free PMC article. Review.

49

Challenges in HER2-low breast cancer identification, detection, and treatment.

Wu Q, Xu L. Wu Q, et al. Transl Breast Cancer Res. 2024 Jan 11;5:3. doi: 10.21037/tbcr-23-48. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 38751682 Free PMC article. Review.

50

A case report of low-dose apatinib in the treatment of advanced triple-negative breast cancer.

Lv Y, Zhang H, Zhao Y, Zhang H, Wang T. Lv Y, et al. Transl Breast Cancer Res. 2024 Jan 11;5:8. doi: 10.21037/tbcr-23-24. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 38751676 Free PMC article.

51

Poland syndrome combined with breast cancer: a case report.

Guo S, Chen Y, Li Q, Xie Y, Hao X, Wang J. Guo S, et al. Transl Breast Cancer Res. 2024 Jan 3;5:7. doi: 10.21037/tbcr-23-46. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 38751683 Free PMC article.

52

Tislelizumab: an effective treatment option for early-stage triple-negative breast cancer.

Yu Z. Yu Z. Transl Breast Cancer Res. 2023 Nov 22;5:5. doi: 10.21037/tbcr-23-39. eCollection 2024. Transl Breast Cancer Res. 2023. PMID: 38751685 Free PMC article. No abstract available.

53

Can Hounsfield units on chest CT characterize breast nodules as cystic or solid?

Capaccione K, Desperito E, Asiimwe AC, Salvatore M. Capaccione K, et al. Transl Breast Cancer Res. 2023 Nov 27;5:6. doi: 10.21037/tbcr-23-34. eCollection 2024. Transl Breast Cancer Res. 2023. PMID: 38751680 Free PMC article.

54

TORCHLIGHT trial, brightening the life of more patients with advanced triple-negative breast cancer.

Zhang H, Jin X, Bian L. Zhang H, et al. Transl Breast Cancer Res. 2023 Sep 22;5:1. doi: 10.21037/tbcr-23-33. eCollection 2024. Transl Breast Cancer Res. 2023. PMID: 38751675 Free PMC article. Review.

55

Narrative review on advancing breast cancer treatment: harnessing the power of PD-1/PD-L1 inhibitors for improved patient outcomes.

Zhang F, Wang SS. Zhang F, et al. Transl Breast Cancer Res. 2023 Sep 22;5:2. doi: 10.21037/tbcr-23-23. eCollection 2024. Transl Breast Cancer Res. 2023. PMID: 38751671 Free PMC article. Review.

56

Implications of tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer: clinical oncologist perspectives.

Rosa ML, Reinert T, Pauletto MM, Sartori G, Graudenz M, Barrios CH. Rosa ML, et al. Transl Breast Cancer Res. 2023 Oct 23;5:4. doi: 10.21037/tbcr-23-43. eCollection 2024. Transl Breast Cancer Res. 2023. PMID: 38751669 Free PMC article. Review.

57

Androgen receptor in breast cancer and its clinical implication.

Hackbart H, Cui X, Lee JS. Hackbart H, et al. Transl Breast Cancer Res. 2023 Oct 31;4:30. doi: 10.21037/tbcr-23-44. Epub 2023 Oct 23. Transl Breast Cancer Res. 2023. PMID: 37946721 Free PMC article.

58

Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR⁺HER2^- metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in China.

Balanchivadze N, Robert NJ. Balanchivadze N, et al. Transl Breast Cancer Res. 2023 Oct 23;4:32. doi: 10.21037/tbcr-23-45. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751484 Free PMC article. No abstract available.

59

Interaction of de novo cholesterol biosynthesis and Hippo signaling pathway in ductal carcinoma in situ (DCIS)-comparison with the corresponding normal breast epithelium.

Coradini D. Coradini D. Transl Breast Cancer Res. 2023 Oct 23;4:26. doi: 10.21037/tbcr-23-42. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751474 Free PMC article.

60

Navigating next-generation HR⁺/HER2^- metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression.

Neven P, Dullens L, Han S, Deblander A, Van Herck Y, Van Houdt M, Wildiers H. Neven P, et al. Transl Breast Cancer Res. 2023 Oct 23;4:31. doi: 10.21037/tbcr-23-41. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751459 Free PMC article. No abstract available.

61

CDK4/6 inhibitors for primary endocrine resistant HR-positive/HER2-negative metastatic breast cancer: a case report.

Luo T, Zhu K, Zhong X, He P, Yan X, Tian T. Luo T, et al. Transl Breast Cancer Res. 2023 Oct 7;4:33. doi: 10.21037/tbcr-23-27. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751470 Free PMC article.

62

A clinical perspective on oncoplastic breast conserving surgery.

Heeling E, van Hemert AKE, Vrancken Peeters MTFD. Heeling E, et al. Transl Breast Cancer Res. 2023 Sep 28;4:29. doi: 10.21037/tbcr-23-40. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751480 Free PMC article. Review.

63

New-generation technologies for spatial tissue analysis, indispensable tools for deciphering intratumor heterogeneity in the development of antibody-drug conjugates and radio-immunoconjugates for cancer treatment.

Radosevic-Robin N, Kossai M, Penault-Llorca F. Radosevic-Robin N, et al. Transl Breast Cancer Res. 2023 Sep 20;4:28. doi: 10.21037/tbcr-23-38. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751472 Free PMC article. Review.

64

Reporting breast density on chest computed tomography.

Beizavi Z, Desperito E, Capaccione KM, Patrizio R, Salvatore MM. Beizavi Z, et al. Transl Breast Cancer Res. 2023 Jul 30;4:24. doi: 10.21037/tbcr-23-36. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751487 Free PMC article. Review.

65

Translating new breast ultrasound techniques into clinical practice: evaluating their intended uses and describing other unexpected uses for them.

Ong EMW. Ong EMW. Transl Breast Cancer Res. 2023 Jul 30;4:23. doi: 10.21037/tbcr-23-29. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751486 Free PMC article. Review.

66

Biomarkers derived from CmP signal network in triple negative breast cancers.

Sanchez N, Harvey C, Vincent D, Croft J, Zhang J. Sanchez N, et al. Transl Breast Cancer Res. 2023 Jul 30;4:21. doi: 10.21037/tbcr-23-30. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751477 Free PMC article. Review.

67

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer: a long-term safety and overall survival update from the randomised, double-blind, placebo-controlled, phase 3 trial.

Zhang Q, Li W, Hu X, Sun T, Cui S, Wang S, Ouyang Q, Yin Y, Geng C, Tong Z, Cheng Y, Ning Z, Jiang Z. Zhang Q, et al. Transl Breast Cancer Res. 2023 Jul 30;4:18. doi: 10.21037/tbcr-23-31. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751475 Free PMC article.

68

Real-world efficacy of postoperative radiotherapy with a moderate dose-escalation for phyllodes tumors of the breast.

Álvarez B, Montero A, Ciérvide R, García-Aranda M, Valero J, Chen-Zhao X, López M, Alonso R, García J, Hernando O, Sánchez E, de la Casa MA, Fernandez-Letón P, Rubio C. Álvarez B, et al. Transl Breast Cancer Res. 2023 Jul 30;4:19. doi: 10.21037/tbcr-23-37. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751466 Free PMC article.

69

Features and applications of Ehrlich tumor model in cancer studies: a literature review.

Radulski DR, Stipp MC, Galindo CM, Acco A. Radulski DR, et al. Transl Breast Cancer Res. 2023 Jul 30;4:22. doi: 10.21037/tbcr-23-32. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751464 Free PMC article. Review.

70

Types and progress of clinical trial design for breast cancer: a narrative review.

Zhou T, Zhang J. Zhou T, et al. Transl Breast Cancer Res. 2023 Jul 30;4:20. doi: 10.21037/tbcr-23-22. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751463 Free PMC article. Review.

71

Individualize management for advanced breast cancer with pyrotinib-based anti-HER2 therapy: a case report.

Xu J, Chen J, Huang P, Zhou H, Wang X, Chen Z. Xu J, et al. Transl Breast Cancer Res. 2023 Jul 14;4:25. doi: 10.21037/tbcr-23-26. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751473 Free PMC article.

72

Antibody-drug conjugate monotherapy refines the oncological efficacy as compared to therapy of physicians' choices in advanced breast cancers: a systematic review and meta-analysis.

Song Y, Lv Y. Song Y, et al. Transl Breast Cancer Res. 2023 Apr 30;4:11. doi: 10.21037/tbcr-23-14. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751489 Free PMC article.

73

Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR⁺HER2^- metastatic breast cancer.

Yuan Y, Zhang S, Wang T, Wang B, Wang S, Shi J, Sun T, Yin Y, Ouyang Q, Li J, Wen Y, Zhang L, Jiang Z. Yuan Y, et al. Transl Breast Cancer Res. 2023 Apr 30;4:10. doi: 10.21037/tbcr-23-9. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751483 Free PMC article.

74

HER2-low breast cancer: insights on pathological testing.

Liu Y. Liu Y. Transl Breast Cancer Res. 2023 Apr 30;4:15. doi: 10.21037/tbcr-23-15. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751479 Free PMC article. Review.

75

Updates on the preoperative immunotherapy for triple-negative breast cancer.

Hu H, Kaklamani V. Hu H, et al. Transl Breast Cancer Res. 2023 Apr 30;4:17. doi: 10.21037/tbcr-23-16. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751476 Free PMC article. No abstract available.

76

The association between perioperative opioids and breast cancer recurrence: a narrative review of the literature.

Thomas TE, Bowers K, Gomez D, Morgan O, Borowsky PA, Dutta R, Abu Y, Roy S, Rojas KE. Thomas TE, et al. Transl Breast Cancer Res. 2023 Apr 30;4:12. doi: 10.21037/tbcr-23-6. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751469 Free PMC article. Review.

77

Breast biopsy techniques in a global setting-clinical practice review.

Silva E, Meschter S, Tan MP. Silva E, et al. Transl Breast Cancer Res. 2023 Apr 30;4:14. doi: 10.21037/tbcr-23-12. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751462 Free PMC article. Review.

78

Narrative review on the role of immunotherapy in early triple negative breast cancer: unveiling opportunities and overcoming challenges.

Qian K, Liu Q. Qian K, et al. Transl Breast Cancer Res. 2023 Apr 30;4:16. doi: 10.21037/tbcr-23-17. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751461 Free PMC article. Review.

79

Key points of anti-tumor treatment in breast cancer patients with SARS-CoV-2 infection.

Ge R. Ge R. Transl Breast Cancer Res. 2023 Apr 17;4:13. doi: 10.21037/tbcr-23-10. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751467 Free PMC article. Review.

80

Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy.

Wang X, Li W, Yin Y, Tong Z, Zhang Q, Zheng H, Shao Z, Li H, Yang J, Feng J, Wu F, Lamour F, Restuccia E, Jiang Z. Wang X, et al. Transl Breast Cancer Res. 2023 Jan 31;4:3. doi: 10.21037/tbcr-23-2. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751488 Free PMC article.

81

Chinese Society of Breast Surgery (CSBrS) Practice Guideline 2022.

Xiang H, Liu Y; Chinese Society of Breast Surgery (CSBrS) of the Chinese Surgical Society of the Chinese Medical Association. Xiang H, et al. Transl Breast Cancer Res. 2023 Jan 31;4:2. doi: 10.21037/tbcr-22-50. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751482 Free PMC article. Review.

82

Prospect of neoadjuvant/adjuvant immunotherapy in early-stage triple-negative breast cancer.

Hao X, Gao X, Yin S, Jiang Z. Hao X, et al. Transl Breast Cancer Res. 2023 Jan 31;4:6. doi: 10.21037/tbcr-23-4. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751481 Free PMC article. Review.

83

Advances of HER2 testing for women with breast cancer.

Chivukula M. Chivukula M. Transl Breast Cancer Res. 2023 Jan 31;4:9. doi: 10.21037/tbcr-23-3. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751465 Free PMC article. No abstract available.

84

Zefei Jiang: when ideals illuminate reality, more breast cancer patients will benefit from the inclusion of T-DM1 in China's national medical insurance catalog.

Bao Y. Bao Y. Transl Breast Cancer Res. 2023 Jan 31;4:1. doi: 10.21037/tbcr-23-8. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751460 Free PMC article. No abstract available.

85

A retrospective cohort study comparing reconstructive techniques and outcomes in post-mastectomy triple negative breast cancer patients.

Sayyed AA, Towfighi P, Deldar R, Aminpour N, Sogunro O, Maini M, Masanam M, Son JD, Fan KL, Song DH. Sayyed AA, et al. Transl Breast Cancer Res. 2023 Jan 29;4:5. doi: 10.21037/tbcr-22-42. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751478 Free PMC article.

86

Molecular subtypes predict the prognosis of male breast cancer: a retrospective cohort study.

Wang M, Liu D, Zhang Z, Dai X, Chen G, Zhu L. Wang M, et al. Transl Breast Cancer Res. 2022 Oct 27;4:4. doi: 10.21037/tbcr-22-24. eCollection 2023. Transl Breast Cancer Res. 2022. PMID: 38751485 Free PMC article.

87

Breast cancer gene expression signatures: development and clinical significance-a narrative review.

Li S, Yu X, Xu Y. Li S, et al. Transl Breast Cancer Res. 2022 Oct 27;4:7. doi: 10.21037/tbcr-22-39. eCollection 2023. Transl Breast Cancer Res. 2022. PMID: 38751471 Free PMC article. Review.

88

Self-detection remains a primary means of breast cancer detection in Beijing, China.

Yang Y, Yu J, Bai Y, Liu A, Tian J, Guo L, Huo D, Zhao P, Ji W, Luo B. Yang Y, et al. Transl Breast Cancer Res. 2022 Apr 8;4:27. doi: 10.21037/tbcr-22-2. eCollection 2023. Transl Breast Cancer Res. 2022. PMID: 38751468 Free PMC article.

89

Clinical considerations for estrogen receptor-negative/progesterone receptor-positive/HER2-negative (ER^-PR⁺HER2^-) breast cancer.

Rala de Paula BH, Crocamo S, Bines J. Rala de Paula BH, et al. Transl Breast Cancer Res. 2022 Oct 28;4:8. doi: 10.21037/tbcr-22-41. eCollection 2023. Transl Breast Cancer Res. 2022. PMID: 38751458 Free PMC article. No abstract available.

90

Risk-reducing surgery in PALB2 mutations carriers with breast cancer: a case series and literature review.

Masanam MK, Pitcher CW, Sogunro O, Starks LK, Murray AB, Boisvert ME. Masanam MK, et al. Transl Breast Cancer Res. 2022 Oct 31;3:37. doi: 10.21037/tbcr-22-33. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751533 Free PMC article.

91

A round table discussion: clinical landscape of trastuzumab deruxtecan in breast cancer: a retrospective and prospective view.

Liang X, Yan Y, Song G. Liang X, et al. Transl Breast Cancer Res. 2022 Oct 31;3:32. doi: 10.21037/tbcr-22-45. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751531 Free PMC article. Review.

92

An engineering feat of small proportions.

Higa GM. Higa GM. Transl Breast Cancer Res. 2022 Oct 31;3:35. doi: 10.21037/tbcr-22-44. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751530 Free PMC article. No abstract available.

93

Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer (2023 edition).

Li J, Wang X, Wang S, Wang S, Wang T, Liu Y, Geng C, Jin F, Yin Y, Zhang Q, Song E, Wu J, Jiang Z; Chinese Society of Clinical Oncology Breast cancer committee; Chinese Anti-Cancer Association; Committee of Breast Cancer Society. Li J, et al. Transl Breast Cancer Res. 2022 Oct 31;3:30. doi: 10.21037/tbcr-22-48. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751529 Free PMC article. Review.

94

Strategies for the treatment of HER2⁺ advanced breast cancer based on clinical practice in Chinese patients: a roundtable discussion.

Ouyang Q, Yan M, Wang X, Zhang Q. Ouyang Q, et al. Transl Breast Cancer Res. 2022 Oct 31;3:33. doi: 10.21037/tbcr-22-49. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751526 Free PMC article. Review.

95

Efficacy and safety of margetuximab plus chemotherapy vs. trastuzumab plus chemotherapy in Chinese patients with pretreated HER2-positive advanced metastatic breast cancer: results from a randomized, open-label, multicenter, phase II bridging study.

Zhang Q, Ouyang Q, Li W, Chiu J, Yan M, Lu YS, Sun S, Li H, Du Y, Wang X, Sun T, Yin Y, Wang H, Ye F, Shen K, Wang J, Pan Y, Wang S, Yang J, Wu X, Dai MS, Cheng J, Teng Y, Su F, Wu X, He J, Fu P, Yang L, Xin Y, Wang X, Jiang Z. Zhang Q, et al. Transl Breast Cancer Res. 2022 Oct 31;3:31. doi: 10.21037/tbcr-22-35. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751523 Free PMC article.

96

CSCO breast cancer management guidelines 2022: Australian perspective.

Yong CH, Gupta A, Joshi R. Yong CH, et al. Transl Breast Cancer Res. 2022 Oct 31;3:36. doi: 10.21037/tbcr-22-46. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751522 Free PMC article. No abstract available.

97

Differences between Japan and China in perioperative pharmacotherapy of early-stage breast cancer in breast cancer guidelines (2022 edition).

Yamanaka T, Yamashita T. Yamanaka T, et al. Transl Breast Cancer Res. 2022 Oct 31;3:34. doi: 10.21037/tbcr-22-40. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751518 Free PMC article. No abstract available.

98

Presentation of metastatic breast cancer as a large bowel obstruction in an elderly female with resultant diverting ileostomy: case report.

Greenseid S, Staudinger K, Morgan R, Blake K. Greenseid S, et al. Transl Breast Cancer Res. 2022 Oct 31;3:38. doi: 10.21037/tbcr-22-27. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751512 Free PMC article.

99

A new pathological assessment method to assess residual lesions after neoadjuvant chemotherapy for breast cancer, residual disease in breast and nodes combined with Ki-67 (RDBN-K).

Han R, Ma Y, Liu Z, Li C, Li S, Kong X, Han M, Liu Y, Geng C. Han R, et al. Transl Breast Cancer Res. 2022 Jul 30;3:24. doi: 10.21037/tbcr-21-39. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751546 Free PMC article.

100

Reduction in tumor grade and Ki-67 in postmenopausal patient with node-positive invasive ductal carcinoma following combination hormone replacement therapy cessation: a case report.

King CA, Masanam MK, Maini AS, Merritt CM, Fan KL, Greenwalt IT. King CA, et al. Transl Breast Cancer Res. 2022 Jul 30;3:29. doi: 10.21037/tbcr-22-26. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751542 Free PMC article.

101

Comments to the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2022.

Toi M, Takada M. Toi M, et al. Transl Breast Cancer Res. 2022 Jul 30;3:21. doi: 10.21037/tbcr-22-31. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751538 Free PMC article. No abstract available.

102

Metastatic breast cancer in a transgender female with history of mantle field radiation and free silicone breast injections: case report.

Phillips M, Timek E. Phillips M, et al. Transl Breast Cancer Res. 2022 Jul 30;3:28. doi: 10.21037/tbcr-22-25. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751536 Free PMC article.

103

A case report of gender-affirming mastectomy in a transgender individual with breast cancer.

Bhagat N, Lautenslager L, Hadad I. Bhagat N, et al. Transl Breast Cancer Res. 2022 Jul 30;3:27. doi: 10.21037/tbcr-22-14. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751534 Free PMC article.

104

Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes.

Sereda EE, Kolegova ES, Kakurina GV, Korshunov DA, Sidenko EA, Doroshenko AV, Slonimskaya EM, Kondakova IV. Sereda EE, et al. Transl Breast Cancer Res. 2022 Jul 30;3:23. doi: 10.21037/tbcr-22-22. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751528 Free PMC article.

105

CSCO expert consensus on the diagnosis and treatment of breast cancer brain metastasis.

Wang T, Chen J, Yang J, Fu M, Hua W, Jia W, Liu Y, Wang B, Yan M, Zhou J, Hao C, Chen J, Ou D, Jiang T, Mao Y, Jiang Z; CSCO expert panel of breast cancer*; CSCO expert panel of breast cancer. Wang T, et al. Transl Breast Cancer Res. 2022 Jul 30;3:22. doi: 10.21037/tbcr-22-30. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751521 Free PMC article. Review.

106

Thoughts on therapy strategy in the era of "after anti-HER2 TKI" in CSCO BC Guidelines 2022.

Bian L, Li F, Jiang Z. Bian L, et al. Transl Breast Cancer Res. 2022 Jul 30;3:26. doi: 10.21037/tbcr-22-32. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751519 Free PMC article. Review.

107

Key points of breast cancer management under public health emergencies.

Ge R, Li J, Jiang Z. Ge R, et al. Transl Breast Cancer Res. 2022 Jul 30;3:25. doi: 10.21037/tbcr-22-28. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751514 Free PMC article. Review.

108

Narrative review of current status and recommendations in treatment for advanced triple-negative breast cancer.

Zhou Y, Yang J. Zhou Y, et al. Transl Breast Cancer Res. 2022 Apr 30;3:17. doi: 10.21037/tbcr-22-12. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751541 Free PMC article. Review.

109

New progress in early breast cancer treatment in 2021.

Shen B, Yang C, Wang K. Shen B, et al. Transl Breast Cancer Res. 2022 Apr 30;3:20. doi: 10.21037/tbcr-22-16. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751540 Free PMC article. No abstract available.

110

Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2022.

Jiang Z, Li J, Chen J, Liu Y, Wang K, Nie J, Wang X, Hao C, Yin Y, Wang S, Yan M, Wang T, Yan Y, Chen X, Song E; CSCO BC guideline working group. Jiang Z, et al. Transl Breast Cancer Res. 2022 Apr 30;3:13. doi: 10.21037/tbcr-22-21. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751537 Free PMC article. Review.

111

Escalating and de-escalating treatments in HR⁺HER2^- early-stage breast cancer.

Ge R. Ge R. Transl Breast Cancer Res. 2022 Apr 30;3:11. doi: 10.21037/tbcr-22-20. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751532 Free PMC article. No abstract available.

112

CDK4/6 inhibitors combined with fulvestrant for HR⁺/HER2^- advanced breast cancer.

Zhang J, Hao C. Zhang J, et al. Transl Breast Cancer Res. 2022 Apr 30;3:10. doi: 10.21037/tbcr-22-17. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751525 Free PMC article. No abstract available.

113

Pseudoangiomatous stromal hyperplasia causing massive unilateral breast enlargement-a case report.

Brodie A, Eltatawy A, Lambert K. Brodie A, et al. Transl Breast Cancer Res. 2022 Apr 30;3:19. doi: 10.21037/tbcr-21-37. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751524 Free PMC article.

114

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guideline update: adjuvant therapy for triple negative breast cancer in 2022.

Ding H, Zhang L, Wang Y, Liu S. Ding H, et al. Transl Breast Cancer Res. 2022 Apr 30;3:12. doi: 10.21037/tbcr-22-13. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751517 Free PMC article. No abstract available.

115

Narrative review of progress in pathological diagnosis of breast cancer.

Liu Y. Liu Y. Transl Breast Cancer Res. 2022 Apr 30;3:16. doi: 10.21037/tbcr-22-11. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751516 Free PMC article. Review.

116

Round table discussion: strategies for the treatment of HER2-positive advanced breast cancer in the rising age of antibody-drug conjugates.

Yan Y, Li Q, Li J. Yan Y, et al. Transl Breast Cancer Res. 2022 Apr 30;3:18. doi: 10.21037/tbcr-21-45. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751515 Free PMC article. Review.

117

The study of correlation between nomogram prediction of uric acid and different chemotherapy regimens in breast cancer patients.

Wang Q, Yang D, Mei J, Li S, Xie S, Zhang H, Dai L, Zhu Z, Lv Y, Yang F, Liu D, Guo R, Tang S. Wang Q, et al. Transl Breast Cancer Res. 2022 Apr 30;3:14. doi: 10.21037/tbcr-21-34. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751510 Free PMC article.

118

Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study.

Wang T, Zhang P, Di L, Wang X, Yang J, Tong Z, Liu J, Feng J, Liu D, Yu Q, Liu Y, Yu H, Jiang Z. Wang T, et al. Transl Breast Cancer Res. 2022 Apr 30;3:15. doi: 10.21037/tbcr-21-42. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751509 Free PMC article.

119

A narrative review of the clinical development of CDK4/6 inhibitor abemaciclib in breast cancer.

Yang L, Chen Y, Wang N, Han W. Yang L, et al. Transl Breast Cancer Res. 2022 Jan 31;3:4. doi: 10.21037/tbcr-21-36. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751545 Free PMC article. Review.

120

Innovation drug approvals based on a bridging study: from concept to practice.

Wang T, Cao X, He Y, Chen X. Wang T, et al. Transl Breast Cancer Res. 2022 Jan 31;3:2. doi: 10.21037/tbcr-21-43. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751544 Free PMC article. Review.

121

Monarch plus: a research review.

Sun T, Xu J, Yang J. Sun T, et al. Transl Breast Cancer Res. 2022 Jan 31;3:7. doi: 10.21037/tbcr-21-6. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751543 Free PMC article. No abstract available.

122

Endocrine therapy leads the first- and second-line treatment options for hormone receptor-positive advanced breast cancer-comments on the Monarch plus study.

Wang X. Wang X. Transl Breast Cancer Res. 2022 Jan 31;3:6. doi: 10.21037/tbcr-21-49. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751539 Free PMC article. No abstract available.

123

Pneumonitis and cellular immunodeficiency triggered by the CDK 4/6 inhibitor Abemaciclib.

Ashraf S, Biglow L, Dotson J, Tirona MT. Ashraf S, et al. Transl Breast Cancer Res. 2022 Jan 31;3:9. doi: 10.21037/tbcr-21-19. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751535 Free PMC article.

124

Role of abemaciclib in primary breast cancer: a narrative review of MonarchE.

Takahashi N, Shimizu C, Shimomura A, Toi M. Takahashi N, et al. Transl Breast Cancer Res. 2022 Jan 31;3:3. doi: 10.21037/tbcr-21-27. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751527 Free PMC article. Review.

125

MONARCH-plus: the evidence of efficacy and safety of abemaciclib in countries with limited clinical research opportunities.

Awada A, Gombos A. Awada A, et al. Transl Breast Cancer Res. 2022 Jan 31;3:5. doi: 10.21037/tbcr-21-25. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751520 Free PMC article. No abstract available.

126

The legend of MONARCH: Chinese breast cancer experts from participation in to leading global clinical study and boosting treatment area development.

Liu Q. Liu Q. Transl Breast Cancer Res. 2022 Jan 31;3:1. doi: 10.21037/tbcr-22-6. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751513 Free PMC article. No abstract available.

127

Sequential versus concurrent adjuvant chemo-endocrine therapy for HR+ early breast cancer: a systematic review and Bayesian network meta-analysis.

Li T, Shan Z, Shi Y, Kuang X, Yu L, Tang SC, Shao N, Lin Y. Li T, et al. Transl Breast Cancer Res. 2022 Jan 31;3:8. doi: 10.21037/tbcr-21-3. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751511 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

127 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Results by year